{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:40:56Z","timestamp":1791326456608,"version":"4.3.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease associated with systemic changes in immune response, which might be associated with coronavirus disease 2019 (COVID-19) severity. The aim of this study was to investigate the impact of NAFLD on COVID-19 severity and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective observational study included consecutively hospitalized adult patients, hospitalized between March and June 2021, with severe COVID-19. Patients were screened for fatty liver by ultrasound and subsequently diagnosed with NAFLD. Patients were daily followed until discharge, and demographic, clinical, and laboratory data were collected and correlated to clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 216 patients included, 120 (55.5%) had NAFLD. The NAFLD group had higher C-reactive protein (interquartile range [IQR]) (84.7 [38.6\u2013129.8] mg\/L vs 66.9 [32.2\u201397.3] mg\/L; P\u2005=\u2005.0340), interleukin-6 (49.19 [22.66\u201392.04] ng\/L vs 13.22 [5.29\u201339.75] ng\/L; P\u2005&amp;lt;\u2005.0001), aspartate aminotransferase (58 [40\u201381] IU\/L vs 46 [29\u201382] IU\/L; P\u2005=\u2005.0123), alanine aminotransferase (51 [32\u201373] IU\/L vs 40 [23\u201369] IU\/L; P\u2005=\u2005.0345), and lactate dehydrogenase (391 [285\u2013483] IU\/L vs 324 [247\u2013411] IU\/L; P\u2005=\u2005.0027). The patients with NAFLD had higher disease severity assessed by 7-category ordinal scale, more frequently required high-flow nasal cannula or noninvasive ventilation (26, 21.66%, vs 10, 10.42%; P\u2005=\u2005.0289), had longer duration of hospitalization (IQR) (10 [8\u201315] days vs 9 [6\u201312] days; P\u2005=\u2005.0018), and more frequently had pulmonary thromboembolism (26.66% vs 13.54%; P\u2005=\u2005.0191). On multivariable analyses, NAFLD was negatively associated with time to recovery (hazard ratio, 0.64; 95% CI, 0.48 to 0.86) and was identified as a risk factor for pulmonary thrombosis (odds ratio, 2.15; 95% CI, 1.04 to 4.46).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>NAFLD is associated with higher COVID-19 severity, more adverse outcomes, and more frequent pulmonary thrombosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac073","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T11:14:22Z","timestamp":1644405262000},"source":"Crossref","is-referenced-by-count":29,"title":["Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study"],"prefix":"10.1093","volume":"9","author":[{"given":"Nina","family":"Vrsaljko","sequence":"first","affiliation":[{"name":"University Hospital for Infectious Diseases Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Samadan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudija","family":"Viskovic","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases Zagreb, Zagreb, Croatia"},{"name":"Faculty of Health Studies, University of Rijeka, Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Mehmedovi\u0107","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Budimir","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Vince","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases Zagreb, Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neven","family":"Papic","sequence":"additional","affiliation":[{"name":"University Hospital for Infectious Diseases Zagreb, Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"2022031402203174800_CIT0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cmi.2020.10.017","article-title":"Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review.","volume":"27","author":"Serafim","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022031402203174800_CIT0002","doi-asserted-by":"crossref","first-page":"626425","DOI":"10.3389\/fmed.2021.626425","article-title":"Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis.","volume":"8","author":"Hegyi","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2022031402203174800_CIT0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fimmu.2019.00082","article-title":"The differential roles of T cells in non-alcoholic fatty liver disease and obesity.","volume":"10","author":"Van Herck","year":"2019","journal-title":"Front Immunol"},{"key":"2022031402203174800_CIT0004","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.","volume":"64","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity.","year":"2016","journal-title":"J Hepatol"},{"key":"2022031402203174800_CIT0005","article-title":"Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.","author":"Bramante","year":"2020","journal-title":"medRxiv"},{"key":"2022031402203174800_CIT0006","doi-asserted-by":"crossref","first-page":"100057","DOI":"10.1016\/j.metop.2020.100057","article-title":"The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: a population-based study.","volume":"8","author":"Ghoneim","year":"2020","journal-title":"Metabol Open"},{"key":"2022031402203174800_CIT0007","article-title":"High liver fat associates with higher risk of developing symptomatic COVID-19 infection - initial UK biobank observations.","author":"Roca-Fern\u00e1ndez","year":"2020","journal-title":"medRxiv"},{"key":"2022031402203174800_CIT0008","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jhep.2020.09.006","article-title":"NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - the debate continues.","volume":"74","author":"Mushtaq","year":"2021","journal-title":"J Hepatol"},{"key":"2022031402203174800_CIT0009","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jhep.2020.03.044","article-title":"Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study.","volume":"73","author":"Ji","year":"2020","journal-title":"J Hepatol"},{"key":"2022031402203174800_CIT0010","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.aohep.2020.09.015","article-title":"Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).","volume":"20","author":"Lopez-Mendez","year":"2021","journal-title":"Ann Hepatol"},{"key":"2022031402203174800_CIT0011","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/liv.14575","article-title":"Metabolic-associated fatty liver disease is associated with severity of COVID-19.","volume":"40","author":"Zhou","year":"2020","journal-title":"Liver Int"},{"key":"2022031402203174800_CIT0012","doi-asserted-by":"crossref","first-page":"e0240400","DOI":"10.1371\/journal.pone.0240400","article-title":"In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19.","volume":"15","author":"Forlano","year":"2020","journal-title":"PLoS One"},{"key":"2022031402203174800_CIT0013","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2022031402203174800_CIT0014","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s10620-019-05700-9","article-title":"Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort.","volume":"65","author":"Singh","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2022031402203174800_CIT0015","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1007\/s10620-020-06618-3","article-title":"Hepatic steatosis is associated with increased disease severity and liver injury in coronavirus disease-19.","volume":"66","author":"Chen","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2022031402203174800_CIT0016","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/MEG.0000000000001902","article-title":"Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study.","volume":"33","author":"Mahamid","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2022031402203174800_CIT0017","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.dsx.2021.03.019","article-title":"Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis.","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"2022031402203174800_CIT0018","first-page":"10.1002\/hep4.1802","article-title":"Independent predictors of mortality among patients with NAFLD hospitalized with COVID-19 infection.","author":"Younossi","year":"2021","journal-title":"Hepatol Commun"},{"key":"2022031402203174800_CIT0019","doi-asserted-by":"crossref","first-page":"154244","DOI":"10.1016\/j.metabol.2020.154244","article-title":"Letter to the editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.","volume":"108","author":"Zheng","year":"2020","journal-title":"Metabolism"},{"key":"2022031402203174800_CIT0020","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41366-021-00771-z","article-title":"Obesity, walking pace and risk of severe COVID-19 and mortality: analysis of UK Biobank.","volume":"45","author":"Yates","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"2022031402203174800_CIT0021","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40001-020-00464-9","article-title":"Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis.","volume":"25","author":"Chu","year":"2020","journal-title":"Eur J Med Res"},{"key":"2022031402203174800_CIT0022","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/anae.15532","article-title":"Factors associated with mortality in patients with COVID-19 admitted to intensive care: a systematic review and meta-analysis.","volume":"76","author":"Taylor","year":"2021","journal-title":"Anaesthesia"},{"key":"2022031402203174800_CIT0023","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijid.2020.04.061","article-title":"Mild versus severe COVID-19: laboratory markers.","volume":"95","author":"Velavan","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2022031402203174800_CIT0024","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-230X-9-16","article-title":"Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study.","volume":"9","author":"Oruc","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"2022031402203174800_CIT0025","doi-asserted-by":"crossref","first-page":"104219","DOI":"10.1016\/j.compbiomed.2021.104219","article-title":"meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection?","volume":"130","author":"Singh","year":"2021","journal-title":"Comput Biol Med"},{"key":"2022031402203174800_CIT0026","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis.","volume":"29","author":"Malas","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2022031402203174800_CIT0027","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/eurheartj\/ehaa500","article-title":"Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.","volume":"41","author":"Fauvel","year":"2020","journal-title":"Eur Heart J"},{"key":"2022031402203174800_CIT0028","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19.","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"2022031402203174800_CIT0029","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/M20-2566","article-title":"Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series.","volume":"173","author":"Lax","year":"2020","journal-title":"Ann Intern Med"},{"key":"2022031402203174800_CIT0030","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/infdis\/jiaa578","article-title":"Postmortem findings in Italian patients with COVID-19: a descriptive full autopsy study of cases with and without comorbidities.","volume":"222","author":"Falasca","year":"2020","journal-title":"J Infect Dis"},{"key":"2022031402203174800_CIT0031","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.26510","article-title":"Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.","volume":"59","author":"Verrijken","year":"2014","journal-title":"Hepatology"},{"key":"2022031402203174800_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases.","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res"},{"key":"2022031402203174800_CIT0033","doi-asserted-by":"crossref","first-page":"E287","DOI":"10.1148\/radiol.2021210400","article-title":"Pulmonary angiography for the diagnosis of pulmonary embolism in patients with COVID-19: when, why, and for who?","volume":"299","author":"Porfidia","year":"2021","journal-title":"Radiology"},{"key":"2022031402203174800_CIT0034","doi-asserted-by":"crossref","first-page":"11070","DOI":"10.3390\/ijerph182111070","article-title":"The weight problem: overview of the most common concepts for body mass and fat distribution and critical consideration of their usefulness for risk assessment and practice.","volume":"18","author":"Kesztyus","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2022031402203174800_CIT0035","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/s41366-021-00907-1","article-title":"Body composition predictors of outcome in patients with COVID-19.","volume":"45","author":"Bunnell","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"2022031402203174800_CIT0036","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofab275","article-title":"Visceral adiposity and severe COVID-19 disease: application of an artificial intelligence algorithm to improve clinical risk prediction.","volume":"8","author":"Goehler","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022031402203174800_CIT0037","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.metop.2021.100149","article-title":"Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD).","volume":"12","author":"Zarghamravanbakhsh","year":"2021","journal-title":"Metabol Open"},{"key":"2022031402203174800_CIT0038","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10096-019-03759-w","article-title":"Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection.","volume":"39","author":"Papic","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022031402203174800_CIT0039","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/qjmed\/hcy227","article-title":"Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia.","volume":"112","author":"Nseir","year":"2019","journal-title":"QJM"},{"key":"2022031402203174800_CIT0040","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.3346\/jkms.2021.36.e291","article-title":"Non-alcoholic fatty liver disease and COVID-19 susceptibility and outcomes: a Korean nationwide cohort.","volume":"36","author":"Yoo","year":"2021","journal-title":"J Korean Med Sci"},{"key":"2022031402203174800_CIT0041","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac073\/42438512\/ofac073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac073\/42880618\/ofac073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac073\/42880618\/ofac073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T02:21:05Z","timestamp":1647224465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac073\/6524775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac073","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,2,9]]},"article-number":"ofac073"}}